$1.04
+0.05 (+5.05%)
Open$0.99
Previous Close$0.99
Day High$1.06
Day Low$0.96
52W High$18.64
52W Low$10.63
Volume—
Avg Volume397.1K
Market Cap3.41M
P/E Ratio17.44
EPS$0.84
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,792.3% upside
Current
$1.04
$1.04
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 491.6K | 478.0K | 424.9K |
| Net Income | -25,839 | -25,168 | -22,690 |
| Profit Margin | -5.3% | -5.3% | -5.3% |
| EBITDA | -32,660 | -28,783 | -26,607 |
| Free Cash Flow | -24,331 | -23,138 | -19,951 |
| Rev Growth | +16.5% | +3.1% | +2.3% |
| Debt/Equity | 0.13 | 0.11 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |